MEDICINES and HEALTHCARE PRODUCTS REGULATORY AGENCY
SCOPE Web Form
This is a contract result notice, not an open opportunity. Details from the official award data.
This sits in the lower-middle of the IT Services band — a mid-scale opportunity. Based on 36,449 valued IT Services tenders in our corpus.
The Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action aims to help medicines regulators operate pharmacovigilance systems to meet the EU legislative requirements.
Regulators are collaborating to improve skills and capability across the European network, which will help safeguard public health in both national territories and the EU as a whole.
The SCOPE Joint Action will run from 2013 until October 2016.
It has been created to support operations of pharmacovigilance in Europe following new requirements introduced by the European pharmacovigilance legislation that came into effect in June 2012.
Funded by the Consumers, Health and Food Executive Agency (CHAFEA) and with contributions from Member States involved, SCOPE will gather information and expertise on how regulators in Member States run their national pharmacovigilance systems.
Using this information, SCOPE will develop and deliver guidance, training, tools and templates to support good practice.
Through this approach SCOPE aims to support consistent approaches in pharmacovigilance operations in the EU network, which will benefit the safety monitoring of medicines and communications outputs, thereby helping to safeguard public health.
A web-based form for reporting of Adverse Drug Reactions (ADRs) to medicinal products by healthcare professionals and patients is required.
The planned outcome of the process is to provide European National Competent Authorities (NCAs) with a template web-form that can be translated and adapted for use within their own country.
The development of the web based form for reporting of ADRs forms part of Topic 4 (Review of reporting forms) within Work Package 4.
The tool will enhance the engagement of European healthcare professionals and patients, who play an essential role as the primary source of spontaneous ADR information and SCOPE is aiming to facilitate improved ways of ADR reporting to national regulators.
This output from this will be a framework agreement that any European National Competant Authority can call off, the contract will run for a period of three years with the option to extend by a further 12 months.
The requirements are: - A one off piece of work, to produce a web-based form within budget.
This will be ordered by the MHRA on behalf of the SCOPE project. - Optional work to cover customisation; branding, additional fields (if required) for participating countries to integrate the form into their applications and for the translation of the form if needed.
This will be subject to individual call offs (orders) by individual National Authorities.
This Framework will be available for the use of any SCOPE partners as listed on the SCOPE website http://www.scopejointaction.eu/partners/
What the notice asks for
It has been created to support operations
It has been created to support operations of pharmacovigilance in Europe following new requirements introduced by the European pharmacovigilance legislation that came into effect in June 2012.
Using this information, SCOPE will develop
Using this information, SCOPE will develop and deliver guidance, training, tools and templates to support good practice.
Through this approach SCOPE aims to support
Through this approach SCOPE aims to support consistent approaches in pharmacovigilance operations in the EU network, which will benefit the safety monitoring of medicines and communications outputs, thereby helping to safeguard public health.
The planned outcome of the process is
The planned outcome of the process is to provide European National Competent Authorities (NCAs) with a template web-form that can be translated and adapted for use within their own country.
Optional work to cover customisation; branding, additional
Optional work to cover customisation; branding, additional fields (if required) for participating countries to integrate the form into their applications and for the translation of the form if needed.
Sentences from the notice that state an obligation, surfaced automatically and shown in the order they appear. Not an exhaustive list — always confirm against the tender documents.
What this notice demands of you
2 named, none in explicit obligation language. Each one is quoted from the notice.
This output from this will be a framework agreement that any European National Competant Authority can call off, the contract will run for a period of three years with the option to extend by a further 12 months.
This will be ordered by the MHRA on behalf of the SCOPE project.
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at MEDICINES and HEALTHCARE PRODUCTS REGULATORY AGENCY, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- 3858a3a1-7f2d-43f1-ae5a-036ba8d39a7c
- Stage
- contract · Contract
- Source
- Contracts Finder
- Buyer ref
- ITT-1972
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in IT Services
MEDICINES and HEALTHCARE PRODUCTS REGULATORY AGENCY’s tender network